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Abstract
Background: Tamoxifen, a selective estrogen receptor modulator with both estrogenic and anti-
estrogenic activity, is widely used as adjuvant therapy in breast cancer patients. Treatment with
tamoxifen is associated with sexual side effects, such as increased vaginal dryness and pain/
discomfort during sexual activity. There have been limited investigations of the effect of tamoxifen
on estrogen-dependent peripheral genital arousal responses. The objective of this study was to
investigate the effects of tamoxifen on vaginal physiology in the rat.
Methods: Female Sprague-Dawley rats were subjected to sham surgery or bilateral ovariectomy.
After 2 weeks, sham-operated rats were implanted with subcutaneous osmotic infusion pumps
containing vehicle (control) or tamoxifen (150 Pg/day). Ovariectomized rats were similarly infused
with vehicle. After an additional 2 weeks, vaginal blood flow responses to pelvic nerve stimulation
were measured by laser Doppler flowmetry and vaginal tissue was collected for histological and
biochemical assay.
Results: Tamoxifen treatment did not change plasma estradiol concentrations relative to control
animals, while ovariectomized rats exhibited a 60% decrease in plasma estradiol. Tamoxifen
treatment caused a significant decrease in mean uterine weight, but did not alter mean vaginal
weight. Vaginal blood flow was significantly decreased in tamoxifen-infused rats compared to
controls. Similar to ovariectomized animals, estrogen receptor binding was increased and arginase
enzyme activity was decreased in tamoxifen-infused rats. However, different from control and
ovariectomized animals, the vaginal epithelium in tamoxifen-infused rats appeared highly mucified.
Periodic acid-Schiff staining confirmed a greater production of carbohydrate-rich compounds (e.g.
mucin, glycogen) by the vaginal epithelium of tamoxifen-infused rats.
Conclusion: The observations suggest that tamoxifen exerts both anti-estrogenic and pro-
estrogenic effects in the vagina. These physiological alterations may eventually lead to vaginal
atrophy and compromise sexual function.
Published: 13 September 2006
BMC Women's Health 2006, 6:14 doi:10.1186/1472-6874-6-14
Received: 03 April 2006
Accepted: 13 September 2006
This article is available from: http://www.biomedcentral.com/1472-6874/6/14
© 2006 Kim et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BMC Women's Health 2006, 6:14 http://www.biomedcentral.com/1472-6874/6/14
Page 2 of 10
(page number not for citation purposes)
Background
Tamoxifen is a non-steroidal, triphenylethylene derivative
that is widely used and highly effective as adjuvant ther-
apy for the management of breast cancer patients with
estrogen receptor (ER) positive tumors. Originally devel-
oped in the 1960s as a contraceptive agent, tamoxifen was
later found to stimulate ovulation, as well as inhibit the
formation of mammary tumors in rats exposed to carcin-
ogens [1]. While tamoxifen itself is a poor ER ligand, its
metabolite 4-hydroxytamoxifen is a potent antagonist
with high affinity for the ER [2,3]. In addition, the effects
of tamoxifen can be stereo-selective. Trans-tamoxifen is
generally considered an anti-estrogen, whereas cis-
tamoxifen is considered to be a weak estrogen. Intercon-
version between these isomers has been shown to occur in
cultured cells [4], but this process remains poorly charac-
terized in vivo.
Acknowledged as a first generation selective ER modulator
(SERM), tamoxifen and/or its metabolites exert anti-estro-
genic effects in breast tissue, estrogenic effects on bone
(increased density) and plasma cholesterol (decreased
levels), and mixed effects in the uterus [1,5,6]. In addition
to the beneficial effects of tamoxifen, its complex, tissue-
specific action can also result in adverse effects in women.
Peri-menopausal symptoms of hot flushes and night
sweats are frequently reported side effects in both pre- and
post-menopausal women on tamoxifen therapy [5-8]. In
pre-menopausal women, tamoxifen has also been
reported to cause oligomenorrhea or amenorrhea with a
return to normal menses after discontinuing tamoxifen
[9]. Yet, the greatest concern has been focused on the
effects of tamoxifen in the uterus. Tamoxifen treatment
increases the relative risk for endometrial cancer [10-12]
and may increase the incidence of endometriosis and uter-
ine mesenchymal (i.e. myometrial) tumors [6].
While the psychological impact of breast cancer diagnosis
and subsequent treatment can cause profound changes in
sexual function, tamoxifen itself may increase the inci-
dence of sexual dysfunctions. Limited studies indicate that
tamoxifen treatment is associated with decreased sexual
interest/desire and increased vaginal dryness and tight-
ness [6,8,13,14]. In a study designed to specifically assess
the effects of tamoxifen on sexual function in women, 22
of 41 sexually active subjects (54%) experienced pain/dis-
comfort during intercourse that was unrelated to previous
chemotherapy [7]. The duration of tamoxifen treatment
ranged from 2 to 24 months with a median duration of 12
months.
Thus, breast cancer patients treated with tamoxifen as
adjuvant therapy may exhibit symptoms of estrogen dep-
rivation, including sexual dysfunction related to altera-
tions in vaginal tissue structure and function. Sexual
health remains an important contributor to quality of life
in breast cancer survivors [15]. The use of tamoxifen as a
prophylactic agent in younger, pre-menopausal women at
risk for breast cancer is expected to increase. Since younger
women may be exposed to tamoxifen for longer periods
of time, determination and consideration of adverse side
effects will be important. In laboratory animal studies that
simulate sexual arousal through activation of pelvic para-
sympathetic nerves, we and others have previously dem-
onstrated that the vaginal responses of increased blood
flow and fluid transudate production are estrogen-
dependent [16-19]. Given the well-acknowledged estro-
gen dependency of genital tissues, the preliminary clinical
association of tamoxifen treatment with sexual dysfunc-
tion in women, and the critical role of estradiol in main-
taining the vaginal response to sexual arousal, we
investigated the effects of tamoxifen on vaginal blood
flow and tissue morphology in the rat. We further assessed
changes in ER expression and arginase activity as estrogen-
dependent markers in the vagina.
Methods
Animals
Mature female Sprague-Dawley rats (strain Crl:CD; 8–10
weeks old; 200–225 g) were purchased from Charles River
Laboratories (Wilmington, MA) and used for investiga-
tion. These studies were approved by the Institutional
Animal Care and Use Committee at the Boston University
School of Medicine. Animals were subjected to sham sur-
gery or bilaterally ovariectomized. After 2 weeks, sham-
operated rats were implanted with subcutaneous osmotic
infusion pumps (model 2002; Alzet, Palo Alto, CA) con-
taining polyethylene glycol 300 (vehicle-infused control
group; CONT, n = 11) or tamoxifen released at a rate of
150 Pg/day (TMX, n = 11). Ovariectomized rats (OVX, n =
8) were similarly infused with vehicle. Two weeks after
pump implantation, in vivo studies were carried out to
assess vaginal blood flow, as described below.
Assessment of estrus cycle phase
For all animals, smears of vaginal cells were prepared
before vaginal blood flow measurements. A cotton swab
moistened in 0.9% saline was inserted into the vagina,
manipulated in a circular fashion and then smeared onto
a glass slide. Samples were fixed with 70% ethanol and
stained with hematoxylin and CytoQuik stain (Fisher Sci-
entific). The phase of the estrous cycle was determined
from the morphological characteristics of the vaginal
cells. All samples were examined by a licensed cytologist.
In vivo assessment of vaginal blood flow
Changes in vaginal blood flow in response to pelvic nerve
stimulation were determined by laser Doppler flowmetry,
as previously described [20]. Briefly, rats were anesthe-
tized with intramuscular injections of ketamine (40 mg/
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kg) and xylazine (4 mg/kg). To continuously monitor sys-
temic blood pressure, a 24-gauge angiocatheter was intro-
duced into the carotid artery and connected to a pressure
channel of the laser Doppler flowmeter (Model BLF21D,
Transonic Systems, Inc., Ithaca, NY). A surface probe
(Type I; Transonic Systems, Inc.) was placed in the vaginal
canal, facing the anterolateral vaginal wall and approxi-
mately halfway between the introitus and the cervix. Uni-
lateral pelvic nerve stimulation (PNS) was accomplished
with a Grass S9 stimulator set at normal polarity and
repeat mode to generate a 30 second train of square waves
with 6 Volt pulse amplitude and 0.8 millisecond pulse
duration at various frequencies (5, 10, 20 Hz). Blood flow
data were recorded as tissue perfusion units (TPU).
Hemodynamic parameters (vaginal blood flow and sys-
temic blood pressure) were continuously recorded (col-
lection rate = 100 Hz) throughout the experiment using
WinDaq software (version 2.15; Dataq Instruments,
Akron, OH). Since blood flow through any given tissue is
dependent upon the systemic blood pressure, we also cal-
culated the instantaneous vascular resistance (systemic
blood pressure/blood flow) at each time point. Using the
vascular resistance plots, the area under the curve (AUC)
for each response was determined.
Determination of plasma estradiol concentration
Blood was drawn at the end of the vaginal blood flow
studies. Plasma samples were sent to the Endocrinology
Laboratory, Animal Health Diagnostic Center at the Cor-
nell University College of Veterinary Medicine (Ithaca,
NY) for determination of estradiol concentration. A solid-
phase radioimmunoassay (RIA) with Coat-A-Count rea-
gents (Diagnostic Products Corp., Los Angeles, CA) was
used. The lower detectable limit of this assay was 8 pg/ml.
Across a wide range of concentrations in the linear range,
the inter-assay variation was 4–8% and the intra-assay var-
iation of replicate samples was 4–7%. The most signifi-
cant potential cross-reactants were estrone (10%),
estrone-E-D-glucuronide (1.8%), estrone-3-sulfate
(0.58%), estriol (0.32%), and estriol-3-glucuronide
(0.012%). All other steroidal compounds, including
tamoxifen, had cross-reactivity that was not detectable or
extremely low (d0.006%).
Tissue procurement
After the completion of the in vivo studies, animals were
exsanguinated and vaginal and uterine tissues were
removed in their entirety, weighed and placed in chilled
physiological salt solution. For histological analyses, vagi-
nas from each treatment group (n = 5 per group) were
opened with a longitudinal incision and a small notch
was cut at the distal end for proper orientation. Tissues
were then immersed in 10% neutral buffered formalin
and stored at 4°C for 24–72 hours. For biochemical stud-
ies, vaginal tissues from 6 animals per treatment group
(CONT and TMX) were frozen in liquid nitrogen and
stored at -80°C until assayed. Due to the lower number of
ovariectomized animals and the smaller amounts of tissue
obtained from this group, a second set of intact controls
and ovariectomized rats (n = 6 per group) were generated
specifically for the biochemical assays.
Preparation of cytosolic and nuclear extracts from vaginal 
tissue
Frozen vaginal tissue was pulverized with a Bessman tis-
sue pulverizer (Spectrum Laboratories, Rancho
Dominguez, CA) cooled on dry ice. Tissue powder from
each treatment group was pooled and combined (1 g/4
ml) with ice cold buffer (20 mM HEPES, pH 7.4, 1 mM
EDTA, 0.25 M sucrose). After the addition of phenylmeth-
ylsulfonylfluoride (PMSF; 0.5 mM) and mammalian pro-
tease inhibitor cocktail (1 mM AEBSF, 0.08 PM aprotinin,
20 PM leupeptin, 40 PM bestatin, 15 PM pepstatin A and
14 PM E-64; Sigma Chemical Co., St. Louis, MO), tissue
powder was homogenized on ice using a Brinkmann
PT3000 polytron with 10 second bursts and 30 second
cooling intervals. The homogenate was centrifuged at
3000 × g for 20 min at 4°C and the supernatant (cytosol)
was transferred to a fresh tube. An aliquot was used to
determine soluble protein concentration and the rest of
the cytosolic extract was frozen at -20°C until further
assay. The pellet containing the nuclei was resuspended in
ice cold buffer (50 mM Tris-HCl, pH 7.4 at 22°C, 1.5 mM
sodium EDTA, 10% glycerol, 10 mM sodium molybdate
and 10 mM monothioglycerol) containing 0.4 M KCl and
homogenized on ice with a Dual glass-glass homogenizer
using a motor driven pestle. The nuclear homogenate was
incubated on ice for 1 hour and centrifuged at 100,000 ×
g for 30 minutes. The resulting supernatant (nuclear
extract) was transferred to a new tube and frozen at -20°C.
Receptor binding assay
Prior to performing the binding assay, free steroid hor-
mone was removed from vaginal tissue extracts by incu-
bating samples with dextran coated charcoal (DCC). An
aliquot of DCC suspension (5 g acid washed charcoal and
0.5 g dextran in 1 liter of 10 mM Tris, pH 7.4 at 2°C, 1.5
mM EDTA, 0.02% NaN3) was placed in a tube and centri-
fuged for 10 min at 1000 × g. The supernatant was aspi-
rated and an equal volume of cytosol/nuclear extract
mixture was added to the DCC pellet. Samples were incu-
bated on ice for 20 min with intermittent mixing and
DCC was removed by centrifugation. Binding studies were
carried out as described previously by Traish et al. [21].
Briefly, aliquots of the DCC-treated vaginal tissue extracts
(100–200 Pl) were mixed with an equal volume of buffer
containing [2,4,6,7,16,17-3H(N)]estradiol (specific activ-
ity = 110 Ci/mmol; Perkin-Elmer Life and Analytical Sci-
ences, Boston, MA) without (total binding) or with a 200-
fold molar excess of unlabeled diethylstilbestrol (non-
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specific binding). Samples were maintained for 24 h at
2°C, followed by incubation at 25°C for 2 h and then re-
incubated at 2°C for 22 h to measure occupied and unoc-
cupied binding sites (exchange assay) [22]. The protein-
bound radioactivity was separated from free radioactivity
by hydroxylapatite assay [21].
Arginase assay
Cytosolic vaginal tissue extract was used to determine
arginase activity, as previously described [23]. Briefly, 10
Pl of tissue extract (triplicate aliquots) were incubated in
buffer (75 mM glycine, pH 9.0, 0.25 mM MnCl2) contain-
ing 300,000 dpm of [14C-guanidino]-L-arginine (51.5
mCi/mmol; NEN Life Science Products, Boston, MA), 4
mM of unlabelled L-arginine in a final volume of 100 Pl.
Samples were incubated for 60 min at 37°C and reactions
were terminated by the addition of 400 Pl of 0.25 M acetic
acid (pH 4.5), 7 M urea, 10 mM L-arginine. After the addi-
tion of 500 Pl of water, samples were passed through a 0.5
ml column of Dowex 50W-X8 resin (Bio-Rad Laborato-
ries, Hercules, CA). Tubes were rinsed twice with 500 Pl of
water and both rinses were poured onto the columns. Col-
umns were washed with an additional 1 ml of water and
all effluent was collected in 20-ml vials. After the addition
of 16 ml of Liquiscint (National Diagnostics, Atlanta,
GA), radioactivity was quantified by liquid scintillation
spectroscopy. Urea production was normalized to total
soluble protein in the tissue.
Histology
After fixation, the mid-section of each vagina was embed-
ded in paraffin and subsequently sectioned at 5 microns
using a rotary microtome. Tissue sections were deparaffi-
nized with CitriSolv (Fisher Scientific, Pittsburgh, PA),
rehydrated in graded ethanol solutions (100–70%), and
subjected to a modified Masson's trichrome and periodic
acid-Schiff (PAS) staining procedure, as previously
described [24].
Data analysis
The results were expressed as mean ± S.E.M. Comparisons
between treatment groups were analyzed by unpaired t-
tests or analysis of variance (ANOVA) followed by post-
hoc comparisons to control (Dunnett's test), as appropri-
ate. Means were considered significantly different if the p-
value was less than 0.05.
Results
Mean plasma estradiol concentration remained unaltered
in tamoxifen treated rats, whereas a significant reduction
in plasma estradiol was detected in ovariectomized rats
(figure 1). Examination of vaginal smears indicated that
all tamoxifen-infused and ovariectomized rats were in die-
strus. In contrast, roughly half (5/11) of the rats in the
control group were in diestrus with 2 each in proestrus,
estrus and metestrus. Minimal changes in body weight
were observed in rats treated with tamoxifen for two
weeks (289 ± 4 g) when compared to age-matched con-
trols infused with vehicle (281 ± 6 g) (figure 2). In con-
trast, ovariectomized rats were significantly heavier (371 ±
6 g). To assess the extent of anti-estrogenic effects of
tamoxifen, the wet weights of the uterus and vagina were
determined for each animal. As shown in figure 2, mean
uterine wet weight was significantly lower in the
tamoxifen treatment group (410 ± 15 mg) than the con-
trol group (644 ± 55 mg), but higher than that of ovariec-
tomized animals (133 ± 4 mg). Interestingly, mean
vaginal wet weight was similar in control and tamoxifen-
infused rats, while a small but significant decrease was
observed in ovariectomized rats.
In vivo studies in anesthetized rats demonstrated fre-
quency-dependent increases in vaginal blood flow in
response to pelvic nerve stimulation. While the percent
reduction in peak vascular resistance was similar at all fre-
quencies of stimulation, the change in total vascular
resistance (AUC) was proportional to the stimulation fre-
quency (figure 3). Consistent reductions in both the per-
cent change in vascular resistance and the area under the
vascular resistance curve indicated that vaginal blood flow
Plasma estradiol measurementsFigure 1
Plasma estradiol measurements. Female Sprague-Dawley rats 
were subjected to sham surgery or bilateral ovariectomy. 
After 2 weeks, sham-operated rats were implanted with sub-
cutaneous osmotic infusion pumps containing vehicle (Con-
trol; CONT) or tamoxifen (TMX; 150 Pg/day). 
Ovariectomized rats (OVX) were similarly infused with vehi-
cle. After an additional 2 weeks, vaginal blood flow studies 
were performed and plasma samples from control (n = 11), 
tamoxifen-infused (n = 11) and ovariectomized (n = 8) rats 
were assayed for estradiol (E2) levels by conventional radio-
immunoassay. Data are the mean ± SEM and were analyzed 
by one-way analysis of variance (ANOVA). *p < 0.05 versus 
control group.
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was significantly decreased in tamoxifen-infused rats (fig-
ure 3).
To further characterize the effects of tamoxifen in the
vagina, we determined ER concentration and arginase
enzyme activity in vaginal tissue extracts. Tamoxifen treat-
ment increased ER levels in the vagina and decreased argi-
nase activity (figures 4 & 5). Similar changes in ER binding
and arginase activity were observed in vaginal tissue
extracts of ovariectomized rats.
Examination of fixed vaginal tissue sections revealed nor-
mal variations in epithelial morphology in intact, cycling
rats. These variations were most apparent at the apical sur-
face of the epithelium and consisted of slightly kerati-
nized, non-keratinized or mucified cells. Mucified
epithelium was characterized by the presence of secretory
vesicles and positive PAS staining (figure 6). A dramatic
increase in the appearance and extent of mucified epithe-
Effect of tamoxifen on vaginal blood flowFigure 3
Effect of tamoxifen on vaginal blood flow. In control (empty 
bars) and tamoxifen-infused (solid bars) rats (see Figure 1), 
changes in vaginal blood flow were measured by laser Dop-
pler flowmetry. Responses to pelvic nerve stimulation at var-
ying frequencies (5–20 Hz) are expressed as the percent 
change in peak vascular resistance (relative to baseline val-
ues) and the area-under-the-curve (AUC). Data are the 
mean ± SEM and were analyzed by two-way ANOVA. *p < 
0.05 versus control group.
Effect of tamoxifen on body and tissue weightsFigure 2
Effect of tamoxifen on body and tissue weights. Body weights 
were determined on the same day as vaginal blood flow stud-
ies in control (CONT), tamoxifen-infused (TMX) and ova-
riectomized (OVX) female rats (see Figure 1). Uterine and 
vaginal tissue wet weights were determined immediately fol-
lowing the blood flow studies. Data are the mean ± SEM and 
were analyzed by one-way ANOVA. *p < 0.05 versus control 
group.
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lium was observed in vaginal tissue from tamoxifen-
treated animals. In addition, this mucified epithelial mor-
phology was observed more frequently in tamoxifen-
infused rats compared to vehicle-infused controls. No
overt differences were noted in the lamina propria and
muscularis layers when comparing vaginal tissue from
control and tamoxifen-treated animals.
Discussion
Sex steroid hormones play a critical role in the develop-
ment and maintenance of female genital tissues. Despite
this widely accepted perspective, characterization of vagi-
nal responsiveness to steroid hormones in the adult has
been limited mainly to the epithelial layer. However, sev-
eral studies in animal models have demonstrated that
fluctuations in ovarian hormones cause measurable
changes in overall vaginal wall thickness, nerve density
and structural organization of the muscularis layer [24-
30]. Biochemical and functional in vivo studies suggest
that estrogens are critical in maintaining vaginal blood
flow, and fluid transudate production [16,17,19,31-33].
In the present study, the tamoxifen-induced changes in
vaginal blood flow, ER expression and arginase activity
were similar to those in ovariectomized animals and
markedly differed from the control group. The trophic
response of the uterus is a sensitive parameter to assess
estrogenic effects. The significant decrease in uterine wet
weight of tamoxifen-infused rats suggests that the dose of
tamoxifen used (150 Pg/day) was physiologically relevant
and effective as an anti-estrogen to inhibit uterine growth.
Tamoxifen treatment significantly reduced vaginal blood
flow responses. This is consistent with our previous stud-
ies in which ovariectomized rats also exhibited a decrease
in vaginal blood flow responses [19]. Thus, we attribute
the decreased vaginal blood flow in tamoxifen-infused
rats to ER antagonism by 4-hydroxytamoxifen.
In addition, increased ER expression and decreased argin-
ase activity were observed in both tamoxifen-infused and
ovariectomized rats in this study. Increased ER levels may
reflect a compensatory up-regulation under conditions of
low estrogen or ER antagonism [19]. Arginase has been
shown to modulate vascular responses in female genital
tissue by decreasing intracellular arginine pools and
inhibiting nitric oxide synthesis through substrate compe-
tition [34]. The decrease in arginase activity in tamoxifen-
infused rats may be reflective of a compensatory down-
regulation in the local vasculature to maintain vaginal
perfusion. Alternatively, since arginase has been shown in
other tissues to be critical for regulating cell growth via the
polyamine synthesis pathway [35,36], the lower arginase
activity may be an early physiological change that eventu-
ally results in vaginal atrophy with prolonged tamoxifen
treatment. Future studies examining the time course of
changes with tamoxifen treatment would be helpful in
this regard. Longer periods (>2 weeks) of tamoxifen treat-
ment may also result in structural changes in the lamina
propria and muscularis layers that were not evident in this
study. Nevertheless, the parallel changes observed in
tamoxifen-infused and ovariectomized rats suggest that
tamoxifen generally exerts an anti-estrogenic effect in the
vagina.
Tamoxifen also exerted a pro-estrogenic effect in the vagi-
nal epithelium. The thickened epithelium and the dra-
matic increase in PAS-positive secretory vesicles within the
apical cells suggested a highly mucified epithelium in
Effect of tamoxifen on vaginal arginase activityFigure 5
Effect of tamoxifen on vaginal arginase activity. Total arginase 
enzyme activity was determined in vaginal tissue extracts 
from control (CONT) and tamoxifen-infused (TMX) rats 
(see Figure 1). For relative comparison, estradiol binding in 
vaginal tissue extracts from control and ovariectomized 
(OVX) rats was determined in separate assays. Data are the 
mean ± SEM from 3 independent assays. *p < 0.05 versus 
control group.
Effect of tamoxifen on vaginal estradiol receptor concentra-tionFigure 4
Effect of tamoxifen on vaginal estradiol receptor concentra-
tion. Total estradiol receptor concentration was determined 
by radioligand binding assay in vaginal tissue extracts from 
control (CONT) and tamoxifen-infused (TMX) rats (see Fig-
ure 1). For relative comparison, estradiol binding in vaginal 
tissue extracts from control and ovariectomized (OVX) rats 
was determined in separate assays. Data are the mean ± SEM 
from 3 independent assays. *p < 0.05 versus control group.
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Effect of tamoxifen on vaginal epitheliumFigure 6
Effect of tamoxifen on vaginal epithelium. Vaginal tissue from control (CONT) and tamoxifen-infused (TMX) rats (see Figure 1) 
were fixed in 10% neutral buffered formalin and embedded in paraffin. Deparaffinized tissue sections (5 Pm) were subjected to 
Masson's trichrome (MT) and periodic acid-Schiff (PAS) staining procedures. For each row, representative tissue sections from 
different animals within each treatment group are shown.
BMC Women's Health 2006, 6:14 http://www.biomedcentral.com/1472-6874/6/14
Page 8 of 10
(page number not for citation purposes)
tamoxifen-infused animals. Since PAS stains all 1,2-glycol
carbohydrates (glycogen, mucins and glycolipids) the spe-
cific identity of the secretory product(s) remained unchar-
acterized. It is also possible that tamoxifen may interfere
with vaginal epithelial differentiation in the rat. While gly-
cogen and mucin production are part of this process, post-
translational modifications of keratins in the apical layer
of the vaginal epithelium have also been shown to be reg-
ulated by estradiol [37,38]. At least one of these processes
(transamidation) is inhibited by tamoxifen [37]. These
post-translational modifications are critical for keratin fil-
ament formation and aggregation. Also, since ER regulates
synthesis of the progesterone receptor (PR), it is possible
that antagonism of ER by tamoxifen results in PR down-
regulation and that PR may be involved in exocytosis of
glycogen from the vaginal epithelium. Thus, tamoxifen
may inhibit the terminal differentiation of vaginal epithe-
lial cells without interfering with intermediate differentia-
tion processes.
It is interesting to note that the estrogenic effects of
tamoxifen on the vaginal epithelium have been observed
by other investigators using animal models [39-41]. Clin-
ical studies have also consistently verified the estrogenic
effects of tamoxifen on the vaginal epithelium [42-47].
However, in breast cancer patients treated with tamoxifen,
although cytological examination of vaginal epithelial
cells indicated a high maturation index, this estrogenic
effect was unrelated to sexual function, duration of
tamoxifen treatment or type of breast cancer surgery [7].
Thus, the relevance of tamoxifen's effect on the vaginal
epithelium to sexual function remains unclear.
Some of the cell and tissue-specific effects of tamoxifen
and its metabolites may be attributed to their multiple
modes of action. In addition to being an ER antagonist,
tamoxifen (and/or its metabolites) has been shown to be
an inhibitor of protein kinase C and a calmodulin antag-
onist [48,49]. In general, these events lead to inhibition of
cell growth and are presumably responsible for
tamoxifen's ability to inhibit tumorigenesis. More impor-
tantly, the interaction of the tamoxifen-bound ER with
various co-activators and co-repressors may be critical in
determining the pro- or anti-estrogenic effects of
tamoxifen [50-52]. Since different cell types may have dif-
ferent levels of protein expression for each co-regulator,
the overall balance of co-regulatory proteins with activat-
ing and repressing activity may determine whether
tamoxifen has an estrogenic or anti-estrogenic effect. In
addition, a membrane protein with characteristics identi-
cal to ERD may stimulate the phosphoinositide pathway
in rat vaginal epithelial cells, [53,54]. However, whether
the epithelium is unique in this regard, relative to other
cell types in the vagina, remains to be established.
A limitation of our study is that we did not investigate the
effects of tamoxifen on testosterone metabolism or andro-
gen receptors. Given that plasma testosterone and estra-
diol both decrease in ovariectomized animals, analogous
changes between tamoxifen-treated and ovariectomized
rats do not necessarily indicate that these changes are due
entirely to estrogen-dependent mechanisms. It is possible
that the effects of tamoxifen are partially dependent upon
androgens. For example, in male rats, tamoxifen has been
shown to decrease circulating levels of luteinizing hor-
mone and testosterone and to increase liver enzymes that
metabolize androgens [55,56]. In postmenopausal
women with breast cancer, tamoxifen treatment resulted
in increased sex hormone binding globulin and decreased
levels of circulating androgens [57]. Further, some studies
suggest that tamoxifen may directly bind the androgen
receptor and can inhibit androgen receptor activity
[58,59]. Thus, the effects of tamoxifen are complex and
may be manifested through multiple and inter-related
receptor systems.
It should be further emphasized that tamoxifen may exert
effects that are species specific. Different responses may
occur due to unique expression profiles of co-activator
and co-repressor proteins. In addition, rats have been
shown to metabolize tamoxifen to hydroxytamoxifen
much more efficiently than humans [60]. Secondary
metabolites produced by the action of sulfotransferases
can also have mutagenic activity through the formation of
DNA adducts. Rat hydroxysteroid sulfotransferase has
been shown to have at least 20-fold greater ability to pro-
duce mutagenic metabolites when compared to the com-
parable human enzyme [61]. Thus, rats may exhibit a
greater sensitivity to both the anti-estrogenic and muta-
genic actions of tamoxifen than humans.
Conclusion
Tamoxifen administration in the female rat causes func-
tional changes in vaginal tissue that parallel the estrogen-
deprived state. Such alterations may eventually lead to
vaginal atrophy, dryness and pain, compromising sexual
function. The apparent pro-estrogenic effect of tamoxifen
on vaginal epithelium and its relevance to sexual function
remains unclear, but is consistent with previous labora-
tory and clinical observations. Vaginal epithelial cells may
manifest a unique expression profile of ER co-regulatory
proteins, as well as membrane-associated and soluble ER
species that enable tamoxifen to mediate an estrogenic
effect on the epithelium while acting as an anti-estrogen
on other cell types in the vagina. The molecular alterations
responsible for the observed functional changes should be
the subject of future studies examining the mixed effects
of tamoxifen (and potentially other SERMs) on the
vagina. Given the current widespread use of tamoxifen in
the management of post-menopausal breast cancer
BMC Women's Health 2006, 6:14 http://www.biomedcentral.com/1472-6874/6/14
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patients, the prospect of increased use of tamoxifen or
other SERMs in younger, premenopausal women at risk
for breast cancer, and the importance of sexual health to
the patient's quality of life, additional research on the
effects of tamoxifen on genital organ function are war-
ranted.
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